Related Experiment Videos
Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target?
Insights
Restenosis after coronary angioplasty is a major issue. New therapies must target both arterial remodeling and neointimal formation, not just the latter, to effectively reduce restenosis.
Area of Science:
- Cardiovascular Research
- Interventional Cardiology
- Vascular Biology
Background:
- Restenosis following percutaneous coronary balloon angioplasty presents a persistent clinical challenge.
- Current therapeutic strategies, successful in animal models, have shown limited efficacy in human trials for reducing restenosis.
- An incomplete understanding of the restenotic process may lead to targeting ineffective mechanisms.
Discussion:
- Restenosis involves not only neointimal hyperplasia but also arterial remodeling, a process of vessel size alteration.
- Arterial remodeling, including constriction or compensatory enlargement, significantly influences lumen patency post-angioplasty.
- Compensatory enlargement can mask substantial neointimal growth, preserving lumen area until critical stenosis occurs.
Key Insights:
- Restenosis should be viewed as a complex response involving both balloon-induced injury and subsequent arterial remodeling.
- Arterial constriction, a form of remodeling, can cause restenosis with minimal neointimal formation.
- Compensatory enlargement allows for significant neointimal accumulation without immediate lumen reduction, complicating treatment.
Outlook:
- Future therapeutic approaches for coronary restenosis must address arterial remodeling alongside neointimal formation.
- Developing treatments that target the mechanisms of arterial remodeling is crucial for improving clinical outcomes.
- A paradigm shift in understanding restenosis may unlock novel therapeutic targets and enhance the success of coronary interventions.
Abstract:
Restenosis after percutaneous coronary balloon angioplasty remains a significant problem. Despite success with a variety of agents in animal models, no agent has proved clearly successful in reducing restenosis in humans. There are many potential reasons for this, but one possibility is that because of our incomplete understanding of the restenotic process, therapy has been directed at the wrong target. Arterial remodeling (changes in total vessel area or changes in area circumscribed by the internal elastic lamina) is well described in de novo atherosclerosis, and there is increasing evidence that this process occurs after angioplasty. Thus, restenosis can be thought of not merely as neointimal formation in response to balloon injury, but as arterial remodeling in response to balloon injury and neointimal formation. Arterial remodeling may consist of actual constriction of the artery, as has been described in some animal models and in preliminary fashion in humans, or of compensatory enlargement as has been described in de novo atherosclerosis and in the hypercholesterolemic rabbit iliac artery model. Arterial constriction can result in restenosis with minimal neointimal formation. Compensatory enlargement accommodates significant amounts of neointimal formation, with preservation of lumen area despite an increase in neointimal area adequate to cause restenosis in a noncompensated artery. This expanded paradigm of arterial remodeling and intimal formation may in part account for the lack of success in clinical trials to date, and therapy directed at arterial remodeling as well as intimal formation may be required to reduce restenosis after coronary interventions.